Allergan submits application to FDA for Oculeve intranasal tear neurostimulator

Allergan has filed a de novo application to the FDA for the Oculeve intranasal tear neurostimulator, according to a company press release. The hand-held stimulator can temporarily increase tear production in patients with dry eye disease due to decreased tear production.